Scottish Intercollegiate Guidelines Network (SIGN) have recently updated their guidance on the pharmacological management of migraine. It was published in March 2023.
The updates are mainly around the use of the newer calcitonin gene-related peptide monoclonal antibodies (see my blogs on these) and the use of medications during pregnancy.
Apart from that there isn’t much that is new here.